Non-core divestments in pharma could herald an increase in IP-rich deal making
Merck Group, Pfizer and Eli Lilly have, in quick succession, announced that they are considering moves to sell large, non-core parts of their businesses. Intellectual property, and its valuation, would inevitably play a large part in such…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.